Terms: = Kidney tumors AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Treatment
69 results:
1. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Kosumi T; Kobayashi M; Shimodaira S; Sugiyama H; Koido S
J Med Case Rep; 2024 Feb; 18(1):88. PubMed ID: 38336778
[TBL] [Abstract] [Full Text] [Related]
2. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
3. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
[TBL] [Abstract] [Full Text] [Related]
4. HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis.
Di Agostino S; Canu V; Donzelli S; Pulito C; Sacconi A; Ganci F; Valenti F; Goeman F; Scalera S; Rollo F; Bagnato A; Diodoro MG; Vizza E; Carosi M; Rufini B; Federici O; Giofrè M; Carboni F; Muti P; Ciliberto G; Strano S; Valle M; Blandino G
Cell Death Dis; 2023 Aug; 14(8):535. PubMed ID: 37598177
[TBL] [Abstract] [Full Text] [Related]
5. The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs.
Yildirim H; Widdershoven CV; Aarts MJ; Bex A; Bloemendal HJ; Bochove-Overgaauw DM; Hamberg P; Herbschleb KH; van der Hulle T; Lagerveld BW; van Oijen MG; Oosting SF; van Thienen JV; van der Veldt AA; Westgeest HM; Zeijdner EE; Aben KK; van den Hurk C; Zondervan PJ; Bins AD
BMC Cancer; 2023 Jul; 23(1):648. PubMed ID: 37434119
[TBL] [Abstract] [Full Text] [Related]
6. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A; Besiroglu B; Adams A; Monsef I; Piechotta V; Tomlinson E; Hornbach C; Dressen N; Goldkuhle M; Maisch P; Dahm P; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2023 May; 5(5):CD013798. PubMed ID: 37146227
[TBL] [Abstract] [Full Text] [Related]
7. [Mucinous tubular and spindle cell carcinoma of kidney: Clinicopathology and prognosis].
Shen Q; Liu YX; He Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):276-282. PubMed ID: 37042138
[TBL] [Abstract] [Full Text] [Related]
8. Lingual metastasis as the first presentation of clear cell renal cell carcinoma: Report of a rare case clinically mimicking a benign lesion.
Kalinin Y; Correia-Neto IJ; do Nascimento SV; de Branco Gonçaves VC; de Andrade BAB; Nonaka CFW; Alves PM; Cunha JLS
Oral Oncol; 2023 Feb; 137():106293. PubMed ID: 36565486
[TBL] [Abstract] [Full Text] [Related]
9. muc1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome.
Lucarelli G; Rutigliano M; Loizzo D; di Meo NA; Lasorsa F; Mastropasqua M; Maiorano E; Bizzoca C; Vincenti L; Battaglia M; Ditonno P
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430448
[TBL] [Abstract] [Full Text] [Related]
10. Clear Cell Renal Cell Carcinoma with Immunotherapy Effect Mimicking Xanthogranulomatous Pyelonephritis.
Wang Y; Ganesan S; Williamson SR; Rayes-Danan R
Int J Surg Pathol; 2023 May; 31(3):316-320. PubMed ID: 35570589
[TBL] [Abstract] [Full Text] [Related]
11. Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature.
Caquelin L; Gewily M; Mottais W; Tebaldi C; Laviolle B; Naudet F; Locher C
BMC Cancer; 2022 Apr; 22(1):381. PubMed ID: 35397511
[TBL] [Abstract] [Full Text] [Related]
12. Chronic hepatitis D-What is changing?
Yardeni D; Heller T; Koh C
J Viral Hepat; 2022 Apr; 29(4):240-251. PubMed ID: 35122369
[TBL] [Abstract] [Full Text] [Related]
13. Bulevirtide for HBV and HDV infections.
Yardeni D; Koh C
Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
[TBL] [Abstract] [Full Text] [Related]
14. Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma.
Lasala R; Santoleri F; Romagnoli A; Musicco F; Abrate P; Costantini A
J Oncol Pharm Pract; 2022 Jun; 28(4):870-883. PubMed ID: 33847190
[TBL] [Abstract] [Full Text] [Related]
15. Primary prostate cancer synchronous with renal cell carcinoma: clinical experience and literature review.
Li ZY; Ying CC; Wan ZH; Wang ZS; Li GH; Chen L; Guo YL
Rom J Morphol Embryol; 2020; 61(2):555-561. PubMed ID: 33544809
[TBL] [Abstract] [Full Text] [Related]
16. [Clinicopathological analysis of clear cell renal cell carcinoma with hemangioblastoma component].
Huang HJ; Chen MJ; Li XO; Zhong DR
Zhonghua Bing Li Xue Za Zhi; 2021 Feb; 50(2):103-107. PubMed ID: 33535303
[No Abstract] [Full Text] [Related]
17. European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma.
Ali S; Camarero J; Hennik P; Bolstad B; Sommerfelt Grønvold M; Syvertsen C; Oddvar Strøm B; Ökvist M; Josephson F; Keller-Stanislawski B; Zafiropoulos N; Pean E; Bergh J; da Rocha Dias S; Pignatti F
ESMO Open; 2020 Nov; 5(6):e000798. PubMed ID: 33188050
[TBL] [Abstract] [Full Text] [Related]
18. Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
[TBL] [Abstract] [Full Text] [Related]
19. Primary renal synovial sarcoma: A case report.
Zhang B; An C; Zhang Y; Tian J; Wang Z; Wang J
Medicine (Baltimore); 2020 Oct; 99(42):e22706. PubMed ID: 33080721
[TBL] [Abstract] [Full Text] [Related]
20. Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects.
Moscetti L; Hennik P; Bolstad B; Camarero J; Josephson F; Melchiorri D; Sommerfelt Grønvold M; Sjoberg J; Botezatu M; Mulder J; Meulendijks D; Trullas Jimeno A; Zafiropoulos N; Bergh J; Enzmann H; Pignatti F
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847837
[TBL] [Abstract] [Full Text] [Related]
[Next]
